Thermo Fisher Scientific Inc. (TMO)

Over the past six months, Thermo Fisher Scientific's stock has experienced some fluctuations and notable events. In October 2023, Thermo Fisher Scientific acquired Olink Holding for $3.1 billion. In February 2025, the company announced the acquisition of Solventum's purification and filtration business for $4.1 billion. In March 2026, Thermo Fisher Scientific completed the acquisition of Clario Holdings, Inc. for $8.8 billion, an acquisition that received EU clearance. In January 2026, Thermo Fisher reported Q4 earnings, surpassing forecasts with adjusted EPS of $6.57 and revenue of $12.22 billion; however, the stock traded lower due to investor focus on margin pressures and a cautious outlook for 2026. In February 2026, Thermo Fisher Scientific increased its quarterly dividend. The stock experienced a more than 15% pullback in its price in early 2026 and hit a 21-week low in mid-March 2026, influenced by broader market sentiment, concerns over profitability, and integration considerations from the Clario acquisition. Despite these pullbacks, the stock has delivered a 13.23% change over the past year.

Information regarding specific demand seasonality for Thermo Fisher Scientific's products and services is not explicitly detailed. However, the company operates in the life sciences and healthcare sectors, which generally exhibit relatively stable demand due to ongoing research, diagnostic needs, and pharmaceutical development. The company's business is considered non-cyclical, with revenue built on recurring demand for consumables. While there might be minor fluctuations related to academic funding cycles or budget allocations in certain customer segments, a strong, pronounced seasonality is not indicated. The company's diverse portfolio across various segments also helps to mitigate significant seasonal impacts on its overall demand.

Thermo Fisher Scientific Inc. is a global life science and clinical research company formed in 2006 through the merger of Thermo Electron and Fisher Scientific. It operates within the laboratory equipment, biotechnology, chemicals, pharmaceutical, and healthcare industries, and is a leading supplier of analytical instruments, clinical development solutions, specialty diagnostics, and a wide range of laboratory, pharmaceutical, and biotechnology services. The company's major products and services are categorized into four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services. The company markets its products under various recognized brand names such as Thermo Scientific, Fisher Scientific, Applied Biosystems, Invitrogen, Patheon, PPD, and Nalgene.

Thermo Fisher Scientific has a significant global presence, serving customers worldwide. The company operates across the Americas, Asia Pacific (APAC), and Europe, Middle East, and Africa (EMEA) regions. The United States is its largest region, accounting for approximately 51.69% of its total revenue in fiscal year 2025, followed by Europe at 26.54% and Asia Pacific at 18.18%.

Thermo Fisher Scientific generally maintains a strong brand reputation as a leader in serving science, known for its innovative technologies and broad range of products and services. Strategic acquisitions and significant investment in the U.S. contribute positively to its reputation. The company's role as a leading responder in the COVID-19 pandemic also highlighted its critical contribution to global health.

Thermo Fisher Scientific's ownership is predominantly institutional, reflecting its status as a core holding in the life sciences sector. Institutional investors hold a dominant stake, approximately 80.05% to 89% of the company's stock. The largest institutional shareholders include The Vanguard Group, Inc., BlackRock, Inc., and State Street Global Advisors, Inc. Retail investors hold the remaining portion, around 5.73% to 19.81%, while insiders own a small percentage, around 0.13%.